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ABSTRACT
Targeting anti-apoptotic proteins can sensitize tumor cells to conventional 
chemotherapies or other targeted agents. Antagonizing the Inhibitor of Apoptosis 
Proteins (IAPs) with mimetics of the pro-apoptotic protein SMAC is one such 
approach. We used sensitization compound screening to uncover possible agents 
with the potential to further sensitize lung adenocarcinoma cells to the SMAC mimetic 
Debio 1143. Several compounds in combination with Debio 1143, including taxanes, 
topoisomerase inhibitors, and bromodomain inhibitors, super-additively inhibited 
growth and clonogenicity of lung adenocarcinoma cells. Co-treatment with Debio 1143 
and the bromodomain inhibitor JQ1 suppresses the expression of c-IAP1, c-IAP2, and 
XIAP. Non-canonical NF-κB signaling is also activated following Debio 1143 treatment, 
and Debio 1143 induces the formation of the ripoptosome in Debio 1143-sensitive cell 
lines. Sensitivity to Debio 1143 and JQ1 co-treatment was associated with baseline 
caspase-8 expression. In vivo treatment of lung adenocarcinoma xenografts with 
Debio 1143 in combination with JQ1 or docetaxel reduced tumor volume more than 
either single agent alone. As Debio 1143-containing combinations effectively inhibited 
both in vitro and in vivo growth of lung adenocarcinoma cells, these data provide a 
rationale for Debio 1143 combinations currently being evaluated in ongoing clinical 
trials and suggest potential utility of other combinations identified here.
INTRODUCTION
The ability of tumor cells to evade apoptosis is 
crucial for tumor biology. The inhibitor of apoptosis 
proteins (IAPs) are important mediators of the anti-
apoptotic phenotype. IAPs are highly expressed in most 
tumors [1]. All eight IAP family members have at least 
one BIR (baculovirus IAP repeat) domain that interacts 
with and inhibits the catalytic activity of caspases [2]. 
Three IAP family members - cIAP1, cIAP2, and XIAP 
- also have RING (really interesting new gene) domains 
with E3 ubiquitin ligase activity [2]. These three IAPs 
modulate ubiquitin-mediated proteasomal degradation 
of proteins and ubiquitin-mediated signaling events [2]. 
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IAP-mediated non-degradative ubiquitination of RIP1 
leads to activation of the inhibitor of NF-κB kinase (IKK), 
phosphorylation and proteasomal degradation of IκBα, and 
nuclear localization of the transcriptional effector subunits 
of NF-κB [2-4]. IAP-mediated ubiquitination of NIK (NF-
κB-inducing kinase) inactivates the non-canonical NF-κB 
pathway [2, 5, 6]. 
Second mitochondrial-derived activator of 
caspases (SMAC) is an endogenous inhibitor of IAPs 
[7]. Stimulation of apoptotic pathways releases SMAC 
from mitochondria; the amino-terminus of SMAC is then 
proteolytically cleaved, exposing a four amino acid motif 
that binds to BIR domains in XIAP, cIAP1, and cIAP-2. 
This prevents IAPs from binding caspases [7-10]. SMAC 
also promotes the auto-ubiquitination and subsequent 
degradation of cIAP1 and cIAP2, but not XIAP [7, 11]. 
Small molecule SMAC mimetics are in various 
stages of clinical development. They function similarly 
to endogenous SMAC by antagonizing the inhibition 
of caspases mediated by XIAP and by inducing the 
auto-ubiquitination of cIAP1 or cIAP2; subsequent NF-
κB-induced expression of TNFα further activates pro-
apoptotic TNFR1 (TNFα receptor) signaling [12-14]. 
Downregulation of the anti-apoptotic protein c-FLIP 
is necessary for sensitivity of breast cancer cell lines to 
SMAC mimetics [15]. SMAC mimetic-induced loss of 
IAP function is also associated with formation of the 
cell-death inducing complex - the ripoptosome [16, 17]. 
However, ripoptosome formation does not require TNFα 
expression. The ripoptosome mediates both caspase-8-
dependent apoptosis and caspase-independent necroptosis 
[16].
Only a subset of non-small cell lung cancer cell lines 
responds to SMAC mimetics as single agents, supporting 
the need for combination therapy treatment [14]. SMAC 
mimetics synergize with conventional chemotherapeutics 
including paclitaxel, gemcitabine, cisplatin, carboplatin 
[18] and the topoisomerase inhibitor SN-38 in a variety of 
tumors (reviewed in [2]). SMAC mimetics also sensitize 
tumor cells to radiation therapy [19, 20]. Here, we describe 
a sensitization screen using the SMAC mimetic Debio 
1143 (AT-406) to identify effective partner agents for the 
treatment of lung adenocarcinoma cells with various driver 
and resistance mutations. Debio 1143 is an orally available 
IAP inhibitor being developed in combination with chemo 
and radiotherapy in various solid tumors (ClinicalTrials.
gov Identifier: NCT01930292) [21]. The combination 
screen revealed novel combinations with Debio 1143 that 
induce apoptosis, intercellular signaling alterations, and 
xenograft efficacy.
RESULTS
Lung adenocarcinoma cell lines are differentially 
responsive to Debio 1143
Six lung adenocarcinoma cell lines, with KRAS, 
EGFR, or ALK driver mutations were evaluated for Debio 
1143 dose-dependent growth inhibition to identify optimal 
concentrations for use in combination assays (Table 1). 
The two most sensitive cell lines, H1975 and H820, have 
EGFR driver mutations and are resistant to erlotinib as 
they harbor gatekeeper T790M mutations. The T790M 
substitution does not affect sensitivity to Debio 1143, as 
matched pairs of erlotinib-sensitive parental and derivative 
erlotinib-resistant (T790M) cell lines have similar Debio 
1143 dose response profiles (Figure S1A). Two of the 
other four lines tested - H2030 (KRAS mutation) and 
H2228 (EML4-ALK translocation) - were less sensitive to 
Debio 1143. A549 and H1650 cells were resistant (Table 
1). Hence, subsets of lung adenocarcinoma lines with three 
different common driver mutations are sensitive to Debio 
1143. 
Debio 1143 combination screen
We sought to identify partner agents that would 
augment efficacy and potency of Debio 1143, using a 
sensitization combination screening format illustrated 
in Figure 1. The six cell lines described in Table 1 were 
screened against 128 agents (Table S1). These compounds 
inhibit a range of different target classes including 
components of growth factor signaling pathways, 
Table 1: GI50, GI25, and GI10 values for Debio 1143 in the panel of lung adenocarcinoma cell lines used for sensitization 
screening
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Figure 1: Schematic of Debio 1143 sensitization screen.
Figure 2: Taxanes, topoisomerase inhibitors, and bromodomain inhibitors sensitize lung adenocarcinoma cell lines to 
Debio 1143 treatment. Growth inhibition curves of docetaxel A., paclitaxel B., SN-38 C., and JQ1 D. in combination with Debio 1143. 
Blue curves indicate growth inhibitory response to docetaxel, paclitaxel, SN-38, or JQ1 in each respective cell line. The three black curves 
indicate the response to the combination of each respective agent and Debio 1143 in each cell line. Growth inhibition is plotted along the 
y-axis of each graph. Debio 1143 concentrations used for each cell line are found in Table 1.
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metabolic and epigenetic modulators, and conventional 
chemotherapeutics. An Area Under the Curve (AUC) 
metric quantified the impact of combinations that inhibited 
growth more effectively and/or more potently than either 
single agent. The top 20% of partner agents ranked by 
AUC (Table S1) include several candidates that are in 
clinical trials or are already US FDA-approved (Table 2). 
Microtubule stabilizers, such as docetaxel (Figure 2A) and 
paclitaxel (Figure 2B) were some of the highest scoring 
compounds across the panel of six cell lines screened in 
combination with Debio 1143. Topoisomerase inhibitors, 
such as SN-38 (Figure 2C) or topotecan (Figure S2A), also 
scored highly using the AUC metric. Broadly acting small 
molecules, such as triptolide, JK184, gemcitabine, MS-
275 (HDAC inhibitor), and bortezomib (data not shown) 
also gave robust additive responses in the sensitization 
screen. A subset of lung adenocarcinoma cell lines was 
also sensitive to bromodomain inhibition with both iBET 
(Figure S2B) and JQ1 (Figure 2D). 
Three of the cell lines have EGFR driver mutations 
but are resistant to EGFR inhibition through the common 
T790M resistance mutation (H1975, and H820, which 
is also MET-amplified,) or other mechanisms (H1650). 
These cell lines were more sensitive to several receptor 
tyrosine kinase inhibitors, including the broad kinase 
inhibitors dasatinib and foretinib. The third-generation 
EGFR inhibitor, afatinib (BIBW-2992), combined super-
additively with Debio 1143 to inhibit growth of mutant 
EGFR lung adenocarcinomas. Debio 1143 sensitized 
cells to co-treatment with a second agent for one of the 
two mutant KRAS cell lines in the screen - H2030. This 
is especially interesting as H2030 is relatively resistant 
to approximately 100 single agents that we tested 
with a broad range of targets (data not shown). Debio 
1143 sensitized H2030 cells to inhibition of Polo-like 
kinase, PI3 kinase, MEK, and BCL-2 family members 
(data not shown). Other combinations with Debio 1143 
were no more effective than either agent alone, or were 
antagonistic. They included receptor tyrosine kinase 
inhibitors, such as AZD-4547, sunitinib, and crizotinib. 
AKT inhibition also did not sensitize cells to Debio 1143 
treatment. Taken together, the screen revealed several 
combinations with enhanced growth inhibitory activity 
on a variety of lung adenocarcinoma cell lines, as well 
as several combinations that did not enhance growth 
inhibition. 
Synergistic Debio 1143 combinations
Synergistic growth inhibition could not be 
determined with the small number of dose points used 
initially, but can be formally evaluated by calculating 
combination index values [26]. We were particularly 
interested in the taxanes as they were among the highest 
scoring combinations by the AUC metric, and because 
the combination of Debio 1143 with paclitaxel and 
carboplatin is in clinical trials for squamous non-small 
cell lung cancer, platinum-refractory ovarian cancer, 
and triple-negative breast cancer (NCT01930292). 
Debio 1143 was more effective and potent at inhibiting 
growth in combination with either paclitaxel (Figure 
3A) or docetaxel (Figure 3B). Debio 1143 was also more 
effective in combination with SN-38 (the active metabolite 
of irinotecan) or with the bromodomain inhibitor JQ1 
(Figure 3C and 3D, respectively). Almost all combinations 
tested in Figure 2 were synergistic based upon the Chou-
Talalay combination indices derived from the curves in 
Figure 3A-3D. The only exception was the combination 
of Debio 1143 and SN-38 in H2030 cells; this interaction 
was additive, but not synergistic. 
We next evaluated the effects of these three 
combinations on cell clonogenicity. Debio 1143 reduced 
clonogenicity of H1975 and H2030 cells, but not A549 
cells, consistent with the original screening data (Figure 
S3). Debio 1143 in combination with all three agents 
substantially reduced clonogenicity compared to vehicle-
treated cells. This included A549 cells, which were 
resistant to Debio 1143 as a single agent (Figure S3).
Debio 1143, alone and in combinations, could affect 
cell accumulation and clonogenicity through impact on 
cell proliferation and/or on cell survival. Over a period 
of 24 hours, Debio 1143 alone induced moderate poly-
ADP ribose polymerase (PARP) cleavage in H1975 and 
H2030 cells; cleaved PARP levels were greatly enhanced 
in the presence of paclitaxel, SN38, or JQ1 in H1975 and 
H2030 cells (Figure 3E, 3F, and 3G). Debio 1143 induced 
no PARP cleavage in A549 cells, which are resistant to this 
agent in CellTiterGlo and clonogenic growth assays. In 
A549 cells, the extent of PARP cleavage in combinations 
was similar to that induced by the single partner agents. 
The impact of longer-term 72 hours treatment on apoptosis 
was determined by Annexin V/propidium iodide flow 
cytometry. Debio 1143 plus JQ1 induced apoptosis in the 
combination-sensitive lines H1975 and H2030, but not 
the combination-resistant line A549 (Figure3H). Overall, 
Debio 1143 is effective as a single agent and induces 
apoptosis in combination with compounds with diverse 
mechanisms of action. 
Signaling impact of Debio 1143 and JQ1 co-
treatment
Modulation of PI3K and MAPK signaling has 
shown benefit in lung adenocarcinoma cell lines. Co-
treatment with Debio 1143 and JQ1 reduced pAKT(S473) 
and p70S6K (phospho and total) in H2030 and A549 
cells, but not in H1975 (Figure S4). The Debio 1143/
JQ1 combination reduced pERK in A549 and H2030, 
but increased pERK in H1975 cells (Figure S4). Hence, 
sensitivity to Debio 1143 plus JQ1 was not tightly 
correlated with PI3K or MAPK signaling in these lines. 
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Figure 3: Debio 1143 synergizes with several agents to inhibit growth of lung adenocarcinoma cell lines and induce 
apoptosis. A.-D. Fixed-concentration growth inhibition assays were performed with four different Debio 1143-containing combinations 
- A. Debio 1143 and paclitaxel; B. Debio 1143 and docetaxel; C. Debio 1143 and SN-38; D. Debio 1143 and JQ1. (E-G) Immunoblots 
with indicated primary antibodies following treatment with Debio 1143 and paclitaxel E., SN-38 F., or JQ1 G. combinations. H. Annexin 
V/propidium iodide flow cytometry following Debio 1143 and/or JQ1 treatment. Annexin V (AV+) only stained cells considered early 
apoptotic. Propidium iodide-only stained plus dual Annexin V- and propidium iodide-stained positive cells considered late apoptotic. Both 
early and late apoptotic populations added together for statistical purposes. ** p < 0.01, *** p < 0.001. H1975 = Debio 1143 (25 µM), JQ1 
(400 nM); H2030 = Debio 1143 (50 µM), JQ1 (1 µM); A549 = Debio 1143 (50 µM), JQ1 (400 nM). 
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SMAC mimetics and bromodomain inhibitors 
modulate the NF-κB pathway [5, 6, 12]. We evaluated the 
impact of Debio 1143 and JQ1, alone or in combination, 
on the canonical and non-canonical arms of the NF-κB 
pathway. The combination, but neither single agent, 
elevated IκBα, an NF-κB inhibitor (Figure 4A). Activity 
of the non-canonical and canonical NF-κB pathway is 
marked by nuclear localization of effectors p52 and p50, 
respectively. Debio 1143, but not JQ1, induced nuclear 
localization of p52 in each cell line tested - H1975, A549, 
and H2030, with no augmentation by the combination 
(Figure 4B, 4C, and 4D). Debio 1143 induced nuclear 
localization of p50 in all three cell lines (Figure 4B, 4C, 
and 4D). However, the combination restored nuclear p50 
protein levels to baseline levels in H1975 cells (Figure 
4B). The combination only slightly decreased nuclear p50 
protein levels in combination-treated A549 cells (Figure 
4C). Furthermore, an increase in p50 nuclear localization 
was seen from vehicle-treated to Debio 1143-treated cells 
and Debio 1143-treated cells and combination-treated 
H2030 cells (Figure 4D). Hence, combination of Debio 
1143 and JQ1 induces the non-canonical NF-κB signaling 
cascade, and canonical NF-κB signaling is repressed to 
baseline levels following combination treatment in the 
combination-sensitive H1975 cell line.
Debio 1143 and JQ1 combination reduces IAP 
levels and induces ripoptosome formation
SMAC mimetics function by inhibiting and 
promoting destruction of IAPs [12-14]. In H1975, H2030, 
and A549 cells, Debio 1143 nearly completely ablates 
cIAP1 (Figure 5A, Figure S5A). JQ1 also moderately 
reduces cIAP1 levels in H1975, A549, and H2030 cells. 
Protein levels of cIAP1 are undetectable in the Debio 
1143/JQ1 combinations (Figure 5A, S5A). Debio 1143 
can also bind cIAP2 and XIAP levels but not to the extent 
seen for cIAP1 [27]. cIAP2 and XIAP levels were most 
completely suppressed following combination treatment 
with Debio 1143 and JQ1 in H1975 cells (Figure 5A). In 
H2030 cells, XIAP levels were reduced below baseline 
levels following JQ1 and combination treatment (Figure 
S5B). The reduction in XIAP levels was surprising since 
XIAP levels are not usually affected by SMAC mimetics 
[7, 11]. cIAP2 levels were also reduced following JQ1 
treatment, but some rebound in cIAP2 protein levels was 
seen in combination-treated H2030 cells (Figure S5B). 
cIAP2 levels were also suppressed in A549 cells following 
the combination treatment, but there was little impact on 
XIAP (Figure S5B). Together, these data indicate that 
suppressing several IAPs is associated with greatest 
growth inhibition of lung adenocarcinoma cells. 
SMAC mimetics can induce expression of TNFα, 
Table 2: Top 27 agents in all cell lines, or either mutant EGFR or KRAS lung adenocarcinoma cells, that best sensitized 
cells to Debio 1143 according to AUC metric. 
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which activates the NF-κB pathway [12-14, 28]. 
Furthermore, JQ1 pleiotropically reduces expression of 
many transcripts including MYC and FOSL1 [29-32]. 
Debio 1143 enhanced TNFα mRNA expression in H2030 
cells, but not H1975 or A549 (Figure 5B), and JQ1 did 
not affect TNFα mRNA expression. However, baseline 
expression of TNFα mRNA was significantly higher in 
H1975 cells than the other two lines (Figure 5C). FOSL1 
transcription was reduced by JQ1 treatment in JQ1-
sensitive cell lines, but no further decrease was observed 
following combination treatment with Debio 1143. Instead, 
Debio 1143 increased expression of FOSL1 in all lines 
tested regardless of sensitivity to the agent (Figure S6A). 
Consistent with other reports for lung adenocarcinoma, 
JQ1 had little impact on MYC mRNA (Figure S6B) [32]. 
Overall, we found no correlation between Debio 1143 
response, JQ1 response, or combination response and 
change in expression of the genes tested. We also found 
no association with response to Debio 1143, JQ1, or the 
combination and histone H3 lysine-27 acetylation or pan-
Figure 4: Debio 1143 and JQ1 treatment activates NF-κB signaling. A. Immunoblots of IκBα protein levels in H1975 cells after 
24 hour treatment. Cellular fractionation of B. H1975, C. A549, and D. H2030 cells following 24 hour treatment with Debio 1143 and/or 
JQ1. Immunoblots with canonical and non-canonical NF-κB signaling components.
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Figure 5: Debio 1143 and JQ1 co-treatment reduces IAP levels and leads to formation of the ripoptosome. A. Immunoblots 
of IAP protein levels following 6 hours of treatment with Debio 1143 and/or JQ1. Arrow indicates band of correct molecular weight for 
cIAP2. B. TNFα mRNA expression following 6 hour treatment with Debio 1143 and/or JQ1.C. Baseline TNFα mRNA expression in H1975, 
A549, and H2030 cells. D. Immunoprecipitation of caspase-8 followed by immunoblots of ripoptosome components to measure formation 
of the ripoptosome following Debio 1143 and/or JQ1 treatment. Cleavage product of RIP1 (p39) indicates active ripoptosome. Cleavage 
product of c-FLIP (p43) indicative of caspase-8 activity and functional ripoptosome. E. Immunoblot of procaspase-8 protein levels.
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acetylation of histone H4 (Figure S6C). 
TNFα induces formation of the ripoptosome, a cell-
death inducing complex that controls both apoptotic and 
necrotic cell death [16, 17]. Caspase-8 and RIP1 (RIPK1) 
are ripoptosome components. In Debio 1143-sensitive 
H2030 and H1975 cells, Debio 1143 alone strongly 
promotes co-immunoprecipitation of RIP1 and c-FLIP 
(especially p43) with caspase-8; this is indicative of 
ripoptosome formation. Further increases in RIP1 and 
caspase-8 co-immunoprecipitation were seen following 
combination treatment (Figure 5D). Both the p39 
cleavage product of RIP1 and the p43 cleavage product 
of c-FLIPL co-immunoprecipitated with caspase-8, 
marking a functional ripoptosome [17, 33]. In contrast, 
co-immunoprecipitation of caspase-8 with RIP1 was not 
observed in three Debio 1143-insensitive cell lines - H441, 
H1650, and A549 (Figure 5D).
Total levels of c-FLIP isoforms (c-FLIPL and 
c-FLIPS) were reduced following JQ1 and combination 
treatment in four of the lines tested regardless of sensitivity 
to Debio 1143. In H2030 cells, only JQ1-treated cells 
showed decreased c-FLIP protein levels, not combination-
treated H2030 cells (Figure 5D). However, total cell lysate 
increases in c-FLIP
p43
 levels were also observed in H2030 
cells treated with JQ1 (alone or in combination with Debio 
1143) (Figure 5D). Combined, these results indicate a 
functioning ripoptosome is formed in the two cell lines 
most sensitive to the combination of Debio 1143 and JQ1. 
Also, inhibition of ripoptosome formation is removed even 
in Debio 1143-insensitive lines following JQ1 treatment. 
Procaspase-8 levels do correlate with greatest response 
to the combination of Debio 1143/JQ1 combination. Of 
the five lines tested for ripoptosome formation, the three 
lines with highest baseline caspase-8 levels were the most 
sensitive to the combination (Figure 5E). Although H441 
is insensitive to Debio 1143 treatment, the combination of 
Debio 1143 and JQ1 super-additively inhibits growth more 
than either agent alone (Figure S7). Overall, ripoptosome 
formation correlates with Debio 1143 sensitivity and JQ1 
reduces protein levels of anti-apoptotic c-FLIP. Debio 
1143 and JQ1 combination sensitivity are more closely 
associated with baseline procaspase-8 protein levels than 
with ripoptosome formation. 
Debio 1143-containing combinations inhibits 
xenograft growth of lung adenocarcinomas
Xenografts of H1975 and A549 cells were implanted 
in nude mice to test the efficacy of Debio 1143 in 
combination with either JQ1 or docetaxel. Limited effects 
of the combination of Debio 1143 and JQ1 treatment on 
tumor volume were observed in H1975 xenografts treated 
with 30mg/kg Debio 1143; 25mg/kg JQ1 (maximum 
%treated/control [%T/C] = 52.7%) (Figure 6A). At these 
drug concentrations, body weights were reduced early 
in treatment, indicative of toxicity, but body weights 
stabilized over time (Figure 6B). Pro-inflammatory dose 
limiting toxicity was observed at higher doses of each 
agent (data not shown). In contrast, little overt toxicity was 
observed for the combination of Debio 1143 and docetaxel 
at 100mg/kg Debio 1143; 8mg/kg docetaxel (Figure 6D), 
which was highly effective on A549 xenografts (maximum 
%T/C = 20.5%) (Figure 6C).
DISCUSSION
Drug combination treatments are essential for more 
effective cancer therapies. Here, we describe a combination 
screen of the SMAC mimetic Debio 1143 with 128 other 
agents against a panel of lung adenocarcinoma cell lines. 
Sensitivity to Debio 1143 was not associated with any 
mutational genotype. Debio 1143 in combination with the 
microtubule stabilizer paclitaxel, topoisomerase inhibitor 
SN-38, or the bromodomain inhibitor JQ1 synergistically 
inhibited growth and clonogenicity, and induced apoptosis 
in lung adenocarcinoma cells. Debio 1143 reduced levels 
of cIAP1 in all lines tested and variably affected other 
IAPs. Debio 1143 also modulated NF-κB signaling with 
increasing nuclear localization of p52 (non-canonical 
signaling). Debio 1143/JQ1 combination treatment 
impaired canonical p50 nuclear localization in the most 
Debio 1143-sensitive cell line tested. Furthermore, the 
combination of Debio 1143 and JQ1 induced formation 
of the cell-death inducing ripoptosome complex. 
Procaspase-8 protein levels most closely correlated with 
sensitivity to the combination of Debio 1143 and JQ1. 
Debio 1143 in combination with JQ1 or docetaxel gave 
modest to robust in vivo growth inhibition, respectively, 
in lung adenocarcinoma xenografts. 
Cell cycle and checkpoint inhibitors, such as the 
pan-cyclin dependent kinase (CDK) inhibitor flavopiridol 
and polo-like kinase inhibitor 1 (PLK1) BI-2536 among 
others, were among the most effective combination 
partners with Debio 1143 in our combination screen. 
These targets are important in maintaining mutant KRAS 
lung adenocarcinomas [34, 35] suggesting that relieving 
some cellular anti-apoptosis restraints with SMAC 
mimetics may be effective in concert with some of these 
therapies. Tyrosine kinase inhibitors also combined 
effectively with Debio 1143 in our sensitization screen. 
Two cell lines with T790M EGFR gatekeeper mutations 
were especially sensitive to combinations with Debio 1143 
and either afatinib, foretinib, or dasatinib. Foretinib can 
inhibit MET and TAM family receptors (TYRO3, AXL, 
MERTK) [36]. MET is indicated as a source of resistance 
to EGFR inhibitor therapy and crosstalk with EGFR can 
modulate signaling [22, 37]. TAM family receptors are 
also implicated as resiliency receptors that bypass EGFR-
targeted therapy [38]. Dasatinib inhibits Src-family kinases 
implicated in driving EGFR-independent resistance 
mechanisms to EGFR inhibitors [37]. Debio 1143 in 
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combination with MEK inhibition also had great effects 
on KRAS mutant cell lines. MEK inhibitor combinations 
have shown promise for KRAS mutant tumors [39]. 
IAPs are E3-ubiquitin ligases expressed at 
high levels in cancer [1]. SMAC mimetics induce 
conformational changes in cellular IAPs leading to 
auto-ubiquitination and proteasomal degradation [12-
14]. Debio 1143 binds the BIR3 domain of cIAP1 and 
cIAP2 more strongly than XIAP [27]. We found that 
Debio 1143 reduces cIAP1 levels as a single-agent and 
in combinations, regardless of the growth sensitivity of 
cell lines to Debio 1143. Therefore, cIAP1 reduction is 
not sufficient to promote apoptosis. Debio 1143 variably 
reduced XIAP and cIAP2, but all three IAPs were 
suppressed in the most sensitive line, H1975. 
Other SMAC mimetics induce non-canonical 
and canonical NF-κB signaling, which was confirmed 
as well for Debio 1143 [5, 6, 12]. Loss of the cellular 
IAPs increases protein levels of NF-κB-inducing kinase 
(NIK), facilitating the activity of the non-canonical NF-
κB signaling pathway [12, 40]. Induction of canonical 
NF-κB signaling radiosensitizes glioblastoma cells and 
can differentiate glioblastoma stem-cell-like cells [19, 
41]. Furthermore, SMAC mimetic-treated pancreatic 
adenocarcinoma cells rely on canonical NF-κB signaling 
to be sensitized to gemcitabine [42]. Activation of the 
canonical NF-κB pathway by SMAC mimetics leads 
to increased TNFα mRNA expression [12-14, 28]. The 
SMAC mimetic sensitive cell lines had strong baseline 
TNFα expression (H1975), or TNFα was strongly 
induced in another (H2030). Increased activity of these 
pathways cannot fully explain the pro-apoptotic effects of 
Debio 1143 because these pathways are active in Debio 
1143-insensitive cells. Therefore, other mechanisms are 
behind the activity of Debio 1143 in this panel of lung 
adenocarcinoma cell lines tested.
Beyond increased NF-κB activity, SMAC mimetic 
treatment and IAP depletion induces ripoptosome 
formation [16, 17]. Depletion of IAPs causes a TNFα-
independent accumulation of RIP1 within the cytosol; 
this accumulation of RIP1 serves as a scaffold for 
ripoptosome formation [16, 17]. In chronic lymphocytic 
leukemia cells, the inability to form ripoptosomes is 
linked to cell line resistance to SMAC mimetic treatment 
[43]. Furthermore, in acute lymphoblastic leukemia, 
ripoptosome components, such as RIP1, are required to 
induce cell death [44]. We found that Debio 1143 induces 
ripoptosome formation in Debio 1143-sensitive cell lines. 
The degree to which the cells form ripoptosomes following 
Debio 1143 treatment did not fully correlate with response 
to Debio 1143. H2030 is less sensitive to Debio 1143 than 
H1975, but H2030 had greater induction or ripoptosome 
Figure 6: Debio 1143 in combination with either JQ1 or docetaxel delays growth of H1975 and A549 lung adenocarcinoma 
in xenograft mouse models. Median tumor volume of H1975 xenografts A. or percent body mass change B. following treatment with 
Debio 1143 (30 mg/kg p.o.) and/or JQ1 (25 mg/kg i.p.). Median tumor volume of A549 xenografts C. or percent body mass change D. 
following treatment with Debio 1143 (100 mg/kg p.o.) and/or Docetaxel (8 mg/kg, i.v.). Error bars are for standard deviation. Maximum 
percent tumor volume/control (%T/C) for A. and C. also noted for each treatment arm.
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assembly than H1975 following Debio 1143 treatment. 
This suggests that the degree of ripoptosome assembly is 
less important than just forming the ripoptosome complex 
in order to induce cell death following SMAC mimetic 
treatment.
SMAC mimetics are excellent partner agents for 
combination therapies because they antagonize anti-
apoptotic proteins. Our combination sensitization screen 
uncovered several agents that super-additively combined 
with Debio 1143. Many of these combinations were 
confirmed to be synergistic and apoptosis-inducing, 
underscoring the notion that antagonizing IAPs results in 
chemosensitization.
Bromodomain inhibitors greatly enhance the effects 
of Debio 1143. Bromodomain inhibition leads to broad 
transcriptional and epigenetic changes with complex 
biological outcomes [29-32, 45]. KRAS-driven lung 
adenocarcinomas with wild-type LKB1 are more sensitive 
to bromodomain inhibitor JQ1 than those with alterations 
in LKB1 [31]. This pattern was observed in the three KRAS 
mutant cell lines tested in our panel. H441 has functional 
LKB1 and is sensitive to JQ1 treatment, whereas H2030 
and A549 (non-functional LKB1) were less sensitive to 
JQ1 treatment. Furthermore, JQ1 sensitivity does not 
seem to correlate with MYC mRNA reduction, a common 
mechanism seen in other cancers [29, 30, 32]. Reduction 
in FOSL1 expression may be more likely facilitating 
the effects of bromodomain inhibition in these lung 
adenocarcinoma cells [32].
The closest association between Debio 1143 and JQ1 
combination sensitivity and biological response was with 
components of the ripoptosome. Ripoptosome formation 
correlated with response to Debio 1143 as a single-agent, 
but not in combination as H441 cells were sensitive to 
the combination, but no ripoptosome formation was 
observed following combination treatment. Also, loss of 
both c-FLIPL and c-FLIPS ripoptosome components did 
not correlate with response to the combination. This is 
somewhat surprising given that ripoptosome formation 
is inhibited by c-FLIPL and promoted by c-FLIPS, 
however, this is cell context specific [17, 46]. The p39 
cleavage product of RIPK1 and p43 cleavage product 
of c-FLIPL are indicative of caspase-8 activity [16, 33, 
47]. Caspase-8 is the caspase responsible for facilitating 
ripoptosome-mediated cell death [16, 17]. The most 
striking correlation we were able to see with Debio 
1143 and JQ1 combination sensitivity was with baseline 
protein levels of procaspase-8. Procaspase-8 protein 
levels are overexpressed in lung cancers [48]. JQ1 may be 
contributing to the effects of the combination mechanism 
by depleting c-FLIP levels. Depletion of c-FLIP has 
differential effects on lung adenocarcinoma cell lines, but 
caspase-8 is necessary for lines to be sensitive to c-FLIP 
depletion [49]. By modulating these proteins it is possible 
to enhance sensitivity to SMAC mimetics.
We describe here the potential utility of Debio 1143 
in combination with taxanes, topoisomerase inhibitors, 
or bromodomain inhibitors. The combination of Debio 
1143 with both paclitaxel and carboplatin is in clinical 
trials for lung squamous cell carcinoma, platinum-
refractory ovarian carcinoma, and triple negative breast 
cancer (NCT01930292). Other drug classes that combined 
effectively with Debio 1143 in our screen targeted cell 
cycle and checkpoint kinases, epigenetic modifiers, 
tyrosine kinases, and the NF-κB pathway. Hence the pro-
apoptotic activities of Debio 1143 may enhance response 
to a broad range of therapeutic targets.
In vivo xenograft testing of some combinations 
confirmed modest activity of the combination of Debio 
1443 and JQ1 and marked activity of the Debio 1143 
and docetaxel combination for lung adenocarcinoma. 
With the Debio 1143 and JQ1 combination, there was 
some pro-inflammatory dose limiting toxicity observed. 
Inclusion of anti-inflammatory agents may ameliorate 
some of these effects. We also observed enhanced activity 
in A549 xenografts following Debio 1143 plus docetaxel 
treatment relative to the single agents. This is noteworthy 
as A549 cells were insensitive to this combination in 
our in vitro screen. SMAC mimetics have been reported 
to be more effective in vivo for treatment of pancreatic 
adenocarcinoma cell [28]. It is possible that systemic 
treatment of the whole mouse induces microenvironmental 
changes or alters paracrine signaling which further 
sensitizes the cells to combination treatment. 
We have used sensitization screening to identify 
combination compound regiments with Debio 1143 
to inhibit growth and induce apoptosis of lung 
adenocarcinoma cells. These combinations are excellent 
candidates for further therapeutic development as 
they include agents already in clinical use (taxanes, 
topoisomerase and MEK inhibitors, etc.) or novel 
agents with attractive targets and target interactions 
(bromodomain inhibitors). Our findings provide a 
rationale for the combination of Debio 1143 with 
paclitaxel in an ongoing clinical trial in several cancer 
types (ClinicalTrials.gov Identifier: NCT01930292). 
The especially strong impact of the combination of 
bromodomain inhibitors and SMAC mimetics warrants 
further investigation to identify the most important 
transcriptional targets, and the mechanisms that foster 
cooperation to induce cancer cell apoptosis. 
MATERIALS AND METHODS
Cell culture and antibodies
Lung adenocarcinoma cell lines were cultured as 
described previously [22]. H1975, H2030, A549, H1650, 
and H441 were obtained from the American Type Culture 
Collection (ATCC). H2228 cells were a gift from J. Peter 
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Koo (Yale). PC9, PC9/BRC1, H3255, and H3255 XLR 
were a gift from Katerina Politi (Yale). PC9/BRC1 and 
H3255 XLR cells are EGFR inhibitor resistant cells and 
have the EGFR T790M gatekeeper mutation [23].
Antibodies used include: PARP, phospho-p70S6K, 
p70S6K, phospho-AKTSer473, AKT, phospho-ERK, ERK, 
β-actin, caspase-8 (mouse), p105/p50, and p100/p52 (Cell 
Signaling); RIP1 (BD Pharmingen); caspase-8 (goat), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
(Santa Cruz); histone H3 (Abcam); c-FLIP (Enzo Life 
Sciences).
Combinatorial compound screening (Figure 1A)
Six cell lines were seeded at 1,000 cells per well 
in 16 μL into 384-well plates using a MultiDrop Combi 
Reagent dispenser (Thermo). Plates were centrifuged 
at 1000 x g to evenly disperse cells and cells allowed 
to adhere overnight. The following day, the cells 
were incubated with 20 nL each of 128 compounds 
using a PlateMate Plus automated pipetting system 
(MatrixTechCorp, Thermo). The 128 compounds were 
arrayed on two 384-well master plates with sixty-four 
agents in a five-point, eight-fold dilution series. The 
highest concentration was usually 10 μM of compound. 
After addition of the agents from the compound 
master plates, 4 μL of either 1% DMSO (vehicle control) 
or Debio 1143 diluted in medium at 5X the GI10, GI25, 
or GI50 concentrations was added. The concentrations of 
Debio 1143 were tailored according to experimentally 
determined GI values for each cell line. A MultiDrop 
Combi reagent dispenser (Thermo) distributed Debio 
1143 or vehicle to each well. 20% DMSO was used as 
a complete growth inhibition control. Cells were treated 
in duplicate. 10 μL of CellTiterGlo reagent was added 
to each well after seventy-two hours of incubation and 
luminescence was measured. All plates had Z’-scores of 
0.5 or higher except for two plates with scores of 0.42 
and 0.47.
Growth assays
Cells were plated at 1,500-4,000 cells in 100 μL 
per well into 96-well black-bottom plates and allowed 
to adhere over night. The next day, cells were treated 
with respective compounds. Seventy-two hours later, 
60 μL CellTiterGlo reagent was added to each well and 
luminescence was measured to determine percent growth 
inhibition (%GI).
Vehicle control was highest concentration of DMSO 
used in treatment conditions, between 0.1-0.3% (v/v) 
DMSO. Complete growth inhibition signal control was 
20% (v/v) DMSO.
Statistical analyses
AUC measurements were performed as described 
previously [24]. Combination index (CI) values were 
calculated using CompuSyn software (ComboSyn) for the 
non-automated Chou-Talalay experiments [25].
Colony formation assays
400 cells were plated in six-well plates. Cells were 
treated the next day and then again three days later for a 
total of six days of incubation. Compounds were washed 
off the cells and allowed to grow five more days before 
being stained with 0.01% crystal violet.
Flow cytometry
250,000 cells were plated in each well of a six-
well tissue culture plate. After cells adhered overnight, 
they were treated with compound or DMSO vehicle for 
72 hours. Next, adherent and non-adherent cells were 
collected, resuspended in annexin V binding buffer, and 
stained with both propidium iodide and annexin V-APC 
according to the manufacturer’s protocol (BD Biosciences, 
San Jose, CA). Cells were analyzed using an LSRII flow 
cytometer.
Cell fractionation
Cells were incubated with compounds for 24 
hours. Cells were washed twice with 1X Dulbecco’s PBS 
(without magnesium or calcium) and then collected by 
scraping in a third wash of PBS. The cell solution was 
divided in half. Cells in both portions were collected by 
centrifugation. One of the pellets was lysed in 1% SDS 
buffer (40 mM Tris HCl, pH 7.4; 150 mM NaCl, 1% 
SDS, 10% glycerol), incubated at 100oC for 10 minutes, 
sonicated for 5 minutes (alternating pulses 15 seconds 
on, 15 seconds off) and cleared by centrifugation. 
The remaining cell pellet was washed once with RSB 
(reticulocyte standard buffer [10 mM NaCl, 1.5 mM 
CaCl2, 10 mM Tris HCl, pH 7.4]) and re-centrifuged. The 
wash RSB was removed and the cells were then swelled on 
ice for 10 minutes in 10-20 volumes of RSB. The swollen 
cells were disrupted with a motorized Teflon pestle. The 
nuclei were pelleted at 1,000 x g for 5 minutes at 4°C. 
The supernatant (cytosolic fraction) was removed. The 
nuclear fraction was washed three times more with RSB 
and resuspended in 1% SDS buffer. Nuclear fractions were 
incubated at 100oC for 10 minutes, sonicated, and cleared 
as described for whole cell extracts. Cytosolic fractions 
were cleared three times more by centrifugation, with the 
supernatant transferred after each clearing step. SDS and 
glycerol were added to a final concentration of 1% and 
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10%, respectively, and cytosolic fractions were incubated 
at 100oC for 10 minutes. Comparable cell equivalent 
portions of nuclear and cytosolic fractions were analyzed 
by gel electrophoresis.
RNA isolation and real-time PCR
RNA was isolated and prepared for real-time PCR 
as described previously [22]. Fold changes were calculated 
using the 2-ΔΔCt method normalized to GAPDH transcript 
levels.
Co-immunoprecipitation
Cells were incubated for six hours with compounds. 
Cells were washed twice with 1X Dulbecco’s PBS 
(without magnesium or calcium) and then lysed in 
immunoprecipitation lysis buffer (20 mM Tris-HCl, pH 
7.4; 150 mM NaCl; 1% Triton X-100; 10% glycerol; 
0.5 mM dithiothreitol; Roche Complete protease 
inhibitor cocktail). Approximately 500 μg of protein was 
immunoprecipitated with 2 μg of caspase-8 (Santa Cruz) 
antibody or goat IgG (Santa Cruz) and 20 μL of protein 
A/G agarose beads (Thermo) with rotation at 4°C for two 
hours. Beads were washed four times with the lysis buffer. 
45 μL of 2X Laemmli sample buffer was then added to 
the beads and the samples were incubated at 100oC for 10 
minutes.
Western blotting
Samples were resolved by gel electrophoresis 
and transferred to PVDF membrane. After blocking 
with 5% (w/v) milk in 1X TBS-T (0.1% Tween-20), 
cells were incubated overnight with indicated primary 
antibodies. Wash buffers were chosen according to the 
manufacturers’ recommendations for each antibody. 
Appropriate species-specific horseradish peroxidase-
conjugated secondary antibodies (Thermo) were added 
prior to chemiluminescence detection (Thermo West Pico 
or Femto).
Xenografts
Appropriate approval from the local institutions 
Animal Care and Use Committee was obtained and 
guidelines followed. H1975 (2x106) or A549 (5x106) cells, 
in 100 μL Matrigel, were implanted subcutaneously in the 
right flanks of 6-8 or 4-6 week old, female Balb/c nude 
mice (Shanghai Laboratory Animal Co. LTD, Shanghai, 
China), respectively. Animals were randomized to groups 
of 8 animals with mean group tumor volumes of 150-200 
mm3 and the treatments started the same day. Debio 1143 
(Debiopharm International SA) was administered by oral 
gavage 5 days a week for 3 weeks either at 100 mg/kg 
(A549) or 30 mg/kg (H1975). Docetaxel (NorthCarolina 
Chemlabs) was administrated intravenously once a 
week for 3 weeks (8 mg/kg). JQ1 (Abmole Bioscience 
Co., Limited, Hong Kong) was formulated in 10% 
hydroxypropyl-β-cyclodextrin (Sigma-Aldrich, #C0926) 
and administered by intraperitoneal injection 5 days a 
week for 3 weeks at 25 mg/kg. Tumor volume and mouse 
weight was monitored every 3-4 days. Tumor volume 
measured with the formula V = l x w x w/2.
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